Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Lutherville, MD
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Lutherville, MD
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Silver Spring, MD
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Silver Spring, MD
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Troy, MI
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Troy, MI
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Kansas City, MO
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Mexico, MO
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Mexico, MO
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Lincoln, NE
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Cedar Knolls, NJ
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Cedar Knolls, NJ
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Great Neck, NY
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
New York, NY
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Charlotte, NC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Jacksonville, NC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Jacksonville, NC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Raleigh, NC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Columbia, SC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Germantown, TN
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Nashville, TN
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Ogden, UT
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Bellevue, WA
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Spokane, WA
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
West Bend, WI
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
West Bend, WI
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Site Reference ID/Investigator# 22507
mi
from
Bedford Park,
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Site Reference ID/Investigator# 22507
mi
from
Bedford Park,
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics
Status: Enrolling
Updated:  5/3/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics
Status: Enrolling
Updated: 5/3/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated:  5/4/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated: 5/4/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated:  5/4/2017
Oregon Health and Science University
mi
from
Portland, OR
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated: 5/4/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Vitamin D Supplementation in Warfighters
Genomics of Vitamin D Supplementation and Warfighter Nutritional Resilience
Status: Enrolling
Updated:  5/4/2017
Madigan Army Medical Center
mi
from
Tacoma, WA
Vitamin D Supplementation in Warfighters
Genomics of Vitamin D Supplementation and Warfighter Nutritional Resilience
Status: Enrolling
Updated: 5/4/2017
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated:  5/8/2017
Baylor College of Medicine
mi
from
Houston, TX
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated: 5/8/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated:  5/8/2017
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated: 5/8/2017
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Desert Sun Clinical Research, LLC
mi
from
Tucson, AZ
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Desert Sun Clinical Research, LLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Alliance Clinical Research
mi
from
Oceanside, CA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Alliance Clinical Research
mi
from
Oceanside, CA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Precision Research Institute, LLC
mi
from
San Diego, CA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Precision Research Institute, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
University of Colorado, School of Medicine
mi
from
Aurora, CO
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
University of Colorado, School of Medicine
mi
from
Aurora, CO
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Connecticut Clinical Research Foundation
mi
from
Bristol, CT
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Connecticut Clinical Research Foundation
mi
from
Bristol, CT
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
University of Florida
mi
from
Gainesville, FL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Borland-Groover Clinic
mi
from
Jacksonville, FL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Borland-Groover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Children's Center for Digestive Healthcare
mi
from
Atlanta, GA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Children's Center for Digestive Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Grand Teton Research Group
mi
from
Idaho Falls, ID
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Grand Teton Research Group
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Southwest Gastroenterology
mi
from
Oak Lawn, IL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Southwest Gastroenterology
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Indiana University
mi
from
Indianapolis, IN
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Gastroenterology and Hepatology Service Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Gastroenterology and Hepatology Service Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan
mi
from
Wyoming, MI
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan
mi
from
Wyoming, MI
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Minnesota Gastroenterology, P.A.
mi
from
Plymouth, MN
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Minnesota Gastroenterology, P.A.
mi
from
Plymouth, MN
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
GI Associates and Endoscopy Center-GI Clinical Research Department
mi
from
Flowood, MS
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
GI Associates and Endoscopy Center-GI Clinical Research Department
mi
from
Flowood, MS
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Darthmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Darthmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Click here to add this to my saved trials